

Gland Pharma

Estimate change

TP change

Rating change



Bloomberg	GLAND IN
Equity Shares (m)	165
M.Cap.(INRb)/(USDb)	324.9 / 3.7
52-Week Range (INR)	2131 / 1200
1, 6, 12 Rel. Per (%)	-2/35/14
12M Avg Val (INR M)	506

Financials & Valuations (INR b)

Y/E MARCH	FY26E	FY27E	FY28E
Sales	63.0	72.1	81.1
EBITDA	14.8	18.1	20.6
Adj. PAT	8.9	11.2	13.3
EBITDA Margin (%)	16.8	19.5	20.0
Cons. Adj. EPS (INR)	54.2	68.0	80.4
EPS Gr. (%)	27.8	25.5	18.3
BV/Sh. (INR)	609.6	677.6	758.0
Ratios			
Net D:E	-0.2	-0.3	-0.3
RoE (%)	9.3	10.6	11.2
RoCE (%)	9.2	10.4	11.0
Payout (%)	0.0	0.0	0.0
Valuations			
P/E (x)	36.4	29.0	24.5
EV/EBITDA (x)	20.6	16.4	13.9
Div. Yield (%)	0.0	0.0	0.0
FCF Yield (%)	-1.2	1.8	2.4
EV/Sales (x)	4.8	4.1	3.5

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	51.8	51.8	51.8
DII	32.6	32.9	35.4
FII	7.9	7.4	4.5
Others	7.6	7.9	8.3

FII Includes depository receipts

CMP: INR1,972

TP: INR2,310 (+17%)

Buy

In-line revenue; margin miss transient

Niche approval – Near-term key to reviving growth/profitability

- Gland Pharma (GLAND) delivered in-line revenue in 2QFY26. However, EBITDA/PAT came in below our expectations by 9%/11%. A lower-than-expected share of milestone income and lower tech transfer/CMO business in ROW markets impacted 2QFY26 performance.
- Having said this, GLAND has limited competition products in the pipeline to drive growth in 2HFY26/FY27. The base business is also witnessing an uptick with steady traction in already commercialized products.
- GLAND's work on facility upgrade/modification and the addition of lyophilizers line at Cenexi facility is on track. It is expected to enhance the revenue run rate from 3QFY26 onward.
- GLAND is implementing a two-pronged strategy in GLP-1 opportunity. It is not only adding a customer base but also working on expanding the capacity to cater to future needs of the manufacturing of peptide products.
- We lower our FY26 estimate by 3% and largely maintain our FY27/FY28 estimates. We value GLAND at 33x 12M forward earnings to arrive at a TP of INR2,310.
- We expect a CAGR of 13%/18%/24% in sales/EBITDA/PAT over FY25-28 to INR81b/INR20.6b/INR13.5b, factoring a) a revival in US business on the back of product introduction, b) increased revenue growth prospects in Cenexi after infrastructure upgrade, and c) increasing capacity utilization of GLP-1 pens/cartridge for non-regulated markets in the initial phase of patent expiries in these markets. Maintain BUY.

Cenexi drives revenue; margins remain steady

- 2Q revenue grew 5.8% YoY to INR14.8b (our est: INR15.1b).
- The base business (ex-Cenexi) was stable YoY at INR10.8b. Sales in core markets grew 4% YoY to INR8.5b (57% of sales). RoW sales remained stable at INR1.6b (11% of sales). India sales decreased 24%YoY to INR665m (4% of sales).
- Cenexi sales grew 21% YoY to INR4.1b (28% of sales).
- Gross margin (GM) expanded 370bp YoY to 62.8% due to lower costs of raw materials. EBITDA margin remained stable at 21% (our estimate: 22.7%). Higher employee costs (+240bp YoY as % of sales) and higher other expenses (+130bp YoY as % of sales) were offset by lower raw material costs (down 370bp YoY as % of sales).
- Exl. Cenexi, EBITDA margin was 35% (up 70bp YoY).
- EBITDA grew 5.7% YoY to INR3.1b (our estimate: INR3.4b).
- Adj. PAT rose 12%YoY to INR1.8b (our estimate: INR2.1b).
- In 1HFY26, revenue/EBITDA/PAT grew 7%/21%/30%.

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Research Analyst: Vipul Mehta (Vipul.Mehta@MotilalOswal.com), **Eshita Jain** (Eshita.Jain@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Highlights from the management commentary

- GLAND remains confident of achieving mid-teen (+2%) YoY growth in revenue in FY26. 1H revenue growth was 6.6% YoY.
- 2H YoY growth would be driven by few key launches, volume growth of existing products and better Cenexi performance.
- The milestone income/profit share for the quarter was 4%/13% as % of sales.
- The YoY growth in US base business was driven by 10% volume growth and 6-7% new launches. Lower milestone income dragged down YoY growth in 2Q.
- The goal date for Dalbavancin is in Nov'25. Another product opportunity (Congrelor) is subject to patent expiry/settlement of GLAND's partner with innovator.
- While GM of Cenexi was lower at 67%, GLAND remains confident of achieving GM of 74-75% in FY26.

Consol. - Quarterly perf.

Y/E March	FY25				FY26				(INR m)			
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE	FY25	FY26E	FY26E	
											2QE	Var (%)
Net Sales	14,017	14,058	13,841	14,249	15,056	14,869	16,065	17,055	56,165	63,045	15,159	-1.9
YoY Change (%)	16.0	2.4	-10.4	-7.3	7.4	5.8	16.1	19.7	-0.9	12.3	7.8	
Total Expenditure	11,373	11,088	10,241	10,774	11,378	11,730	12,258	12,910	43,476	48,276	11,718	
EBITDA	2,644	2,970	3,600	3,475	3,678	3,139	3,807	4,144	12,689	14,769	3,441	-8.8
YoY Change (%)	-10.1	-8.3	-3.8	-3.1	39.1	5.7	5.8	19.3	-6.1	16.4	15.9	
Margins (%)	18.9	21.1	26.0	24.4	24.4	21.1	23.7	24.3	22.6	23.4	22.7	
Depreciation	920	938	963	958	1,011	1,063	1,009	1,072	3,779	4,155	948	
Interest	56	61	228	75	115	78	68	59	420	320	76	
Other Income	514	597	585	440	575	842	623	647	2,136	2,687	599	
PBT before EO expense	2,182	2,567	2,993	2,883	3,128	2,839	3,353	3,661	10,626	12,981	3,016	-5.9
PBT	2,182	2,567	2,993	2,883	3,128	2,839	3,353	3,661	10,626	12,981	3,016	-5.9
Tax	745	932	946	1,018	973	1,002	1,006	1,073	3,641	4,054	947	
Rate (%)	34.1	36.3	31.6	35.3	31.1	35.3	30.0	29.3	34.3	31.2	31.4	
Reported PAT	1,438	1,635	2,047	1,865	2,155	1,837	2,347	2,588	6,985	8,928	2,069	-11.2
Adj PAT	1,438	1,635	2,047	1,865	2,155	1,837	2,347	2,588	6,985	8,928	2,069	-11.2
YoY Change (%)	-25.9	-15.8	0.4	-2.7	49.9	12.3	14.7	38.8	-10.9	27.8	26.5	
Margins (%)	10.3	11.6	14.8	13.1	14.3	12.4	14.6	15.2	12.4	14.2	13.6	
EPS	8.7	9.9	12.4	11.3	13.1	11.2	14.3	15.7	42.4	54.2	13	

E: MOFSL Estimates

Key performance Indicators (Consolidated)

Y/E March	FY25				FY26				(INR m)			
	1Q	2Q	3Q	4Q	1Q	2QE	3QE	4QE	FY25	FY26E	FY26E	
INRm											2QE	Var (%)
Core Markets	10,641	10,521	10,398	11,320	11,484	11,614	11,077	12,674	42,880	46,848	10,857	7.0
YoY Growth (%)	24.3	3.2	-13.4	-6.0	7.9	10.4	6.5	12.0	0	9	3.2	
India	527	874	562	525	594	665	635	656	2,488	2,550	612	8.7
YoY Growth (%)	-18.5	-0.2	-26.1	-0.2	12.7	-23.9	13.0	25.0	-11	3	-30.0	
Rest of the world	2,734	2,663	2,881	2,404	2,978	2,590	4,353	3,725	10,682	13,646	3,690	-29.8
YoY Growth (%)	-4.9	0.1	1.4	-14.2	8.9	-2.7	51.1	54.9	-5	28	38.6	
Cost Break-up												
RM Cost (% of Sales)	40.3	40.9	33.4	34.2	34.6	37.2	35.1	34.8	37.2	35.4	36.0	3.5
Staff Cost (% of Sales)	25.4	23.5	24.8	26.2	27.1	25.9	26.1	25.2	25.0	26.0	26.5	-2.3
Other Cost (% of Sales)	15.5	14.5	15.8	15.2	13.9	15.7	15.1	15.7	15.2	15.1	14.8	6.4
Gross Margins (%)	59.7	59.1	66.6	65.8	65.4	62.8	64.9	65.2	62.8	64.6	64.0	-1.9
EBITDA Margins (%)	18.9	21.1	26.0	24.4	24.4	21.1	23.7	24.3	22.6	23.4	22.7	-7.0
EBIT Margins (%)	12.3	14.5	19.0	17.7	17.7	14.0	17.4	18.0	21.8	22.9	16.4	-15.1



Management call highlights

- Approval for a partner in semi-regulated markets for Semaglutide would enable this CMO opportunity for GLAND.
- The 8KL biologics capacity has just started commercialization and the expansion plan to scale the capacity to 23KL is underway.
- Capex for base business is expected to be INR2.5b/INR3b for FY26/FY27.
- In 2Q, Cenexi reported revenue of INR4.1b, gross margin of 67% (vs. 80% QoQ and 69% YoY), and EBITDA loss of INR616m (vs. profit last quarter) due to a planned shutdown.
- Excl. Cenexi, revenue remained stable at INR10.8b, EBITDA grew 3% YoY to INR3.7b, and gross profit margin was 61%, up 515bp YoY.
- Fontenay Site: Infrastructure/equipment upgrades carried out during shutdown. Excluding the shutdown period, production at the facility is on track, with improved order shipments after the commissioning of a new high-speed ampoule line.
- The Braine-l'Alleud site: Two new lyophilizer expected to be completed by CY25.
- Hérouville Facility: The site saw ramp-up in inactivated vaccine and a sterile ophthalmic gel.
- R&D expenses for 2Q were INR614m (5.8% of sales).
- In 2Q, six ANDAs were filed and five were approved, contributing to a cumulative total of 378 ANDA filings in the US (329 approved, 49 pending).

Working to rebuild momentum in core markets; turning the corner at Cenexi

Core markets – Work-in-progress to improvise growth

- After stable sales in core markets in 1Q, GLAND delivered 4% YoY growth in sales to INR8.5b in 2Q. Gradual build-up of base business and new launches enabled a slight improvement in YoY growth in core markets.
- Gross/EBITDA margins for base business stood at 61%/35% in 2Q and 60%/35% in 1HFY26.
- While GLAND exhibited healthy volume growth, milestone income was lower in 1HFY26, impacting growth to some extent.
- GLAND launched seven new molecules in markets related to base business Daptomycin-RTU/Sumatriptan/new strength of Colistimethate in 2QFY26.
- Subsequently, key product launches such as Dalbavancin and the ramp-up of Colistimethate, alongside improved capacity utilization, should improve growth prospects for GLAND.
- It has about 49 ANDAs pending for approval at the end of 1HFY26.
- Looking ahead, Semaglutide is expected to open incremental opportunities in FY27, positioning GLAND as a potential supplier to semi-regulated markets.
- It has additional 10 products under development under the category of ready-to-use (RTU) bags.
- Considering the growth to be driven by volume/niche product approvals, we expect 12% sales CAGR in this segment over FY25-28 to reach INR46b.


Cenexi - Turnaround phase: lower losses, breakeven in sight

- After acquisition, Cenexi business faced multiple challenges, including frequent equipment breakdowns, delays in technology transfers, and regulatory audits, which weighed on its performance and growth.
- Recently, GLAND has been enhancing Cenexi's capabilities in pre-filled syringes/lyophilized vials/opthalmic gels to improve capacity utilization, revenue momentum and profitability.
- Cenexi delivered 20% YoY growth in sales to INR8.7b in 1HFY26.
- Interestingly, Cenexi's gross margin, which has historically ranged at 75-80%, declined in the current quarter. In 2Q, the company reported a gross margin of 67.3%, down 180bp YoY, reflecting lower operating leverage.
- Furthermore, EBITDA margin turned negative at 15%, reversing the positive trend seen in the previous quarter due to reduced capacity utilization and higher fixed cost absorption. Although GLAND reported losses in 1HFY26, EBITDA losses decreased from EUR11m to EUR5m QoQ.
- With EBITDA breakeven expected in 4QFY26 and incremental revenue contribution from planned launches in FY27, we expect 13% sales CAGR in Cenexi business over FY25-28 to INR21.7b.

Maintain BUY


- We lower our FY26 estimate by 3% and largely maintain our FY27/FY28 estimates. We value GLAND at 33x 12M forward earnings to arrive at a TP of INR2,310.
- We expect a CAGR of 13%/18%/24% in sales/EBITDA/PAT over FY25-28 to INR81b/INR20.6b/INR13.5b, factoring a) revival in US business on the back of product introduction, b) increased revenue growth prospects in Cenexi post infrastructure upgrade, and c) increasing capacity utilization of GLP-1 pens/cartridge for non-regulated market in the initial phase of patent expiries in these markets. Maintain BUY.

Exhibit 1: P/E chart



Source: MOFSL, Company, Bloomberg

Exhibit 2: EV/EBITDA chart



Source: MOFSL, Company, Bloomberg

Story in charts

Exhibit 3: Expect 13% revenue CAGR over FY25-28




Exhibit 4: Expect 12% core market sales CAGR over FY25-28




Exhibit 5: Expect ROW sales to post 15% CAGR over FY25-28




Exhibit 6: Expect India sales to post 7% CAGR over FY25-28






Exhibit 7: EBITDA margin to expand 280bp over FY25-28



Source: Company, MOFSL

Exhibit 8: Expect EPS CAGR of 24% over FY25-28



Source: Company, MOFSL

Financials and valuations

Consolidated - Income Statement							(INRm)
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Total Income from Operations	44,007	36,246	56,647	56,165	63,045	72,055	81,141
Change (%)	27.1	-17.6	56.3	-0.9	12.3	14.3	12.6
Total Expenditure	28,906	25,888	43,138	43,476	48,276	53,969	60,531
% of Sales	65.7	71.4	76.2	77.4	76.6	74.9	74.6
EBITDA	15,102	10,358	13,509	12,689	14,769	18,086	20,610
Margin (%)	34.3	28.6	23.8	22.6	23.4	25.1	25.4
Depreciation	1,103	1,467	3,446	3,779	4,155	4,065	4,368
EBIT	13,999	8,890	10,063	8,910	10,614	14,021	16,242
Int. and Finance Charges	52	74	262	420	320	188	188
Other Income	2,239	2,405	1,702	2,136	2,687	2,169	2,881
PBT bef. EO Exp.	16,186	11,220	11,503	10,626	12,981	16,002	18,935
EO Items	0	-685	178	0	0	0	0
PBT after EO Exp.	16,186	10,536	11,325	10,626	12,981	16,002	18,935
Total Tax	4,069	2,735	3,601	3,641	4,054	4,800	5,680
Tax Rate (%)	25.1	26.0	31.8	34.3	31.2	30.0	30.0
Minority Interest	0	0	0	0	0	0	0
Reported PAT	12,117	7,800	7,724	6,985	8,928	11,201	13,254
Adjusted PAT	12,117	8,307	7,839	6,985	8,928	11,201	13,254
Change (%)	21.5	-31.4	-5.6	-10.9	27.8	25.5	18.3
Margin (%)	26.2	21.5	13.4	12.0	13.6	15.1	15.8

Consolidated - Balance Sheet							(INRm)
Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	164	165	165	165	165	165	165
Total Reserves	71,412	79,423	87,074	91,343	1,00,270	1,11,471	1,24,726
Net Worth	71,576	79,587	87,238	91,507	1,00,435	1,11,636	1,24,891
Minority Interest	0	0	0	0	0	0	0
Total Loans	46	45	3,722	3,137	3,137	3,137	3,137
Deferred Tax Liabilities	878	842	1,697	1,627	1,627	1,627	1,627
Capital Employed	72,499	80,473	92,656	96,272	1,05,200	1,16,401	1,29,655
Gross Block	20,910	23,061	47,846	53,570	59,607	65,464	68,935
Less: Accum. Deprn.	5,888	7,355	10,801	14,580	18,734	22,799	27,167
Net Fixed Assets	15,022	15,705	37,045	38,990	40,873	42,665	41,768
Goodwill on Consolidation	0	0	2,423	2,482	2,482	2,482	2,482
Capital WIP	1,907	1,772	2,379	1,506	5,134	2,777	1,805
Total Investments	1,549	0	6,559	0	0	0	0
Curr. Assets, Loans&Adv.	59,858	70,298	57,703	68,751	73,922	84,990	1,02,141
Inventory	11,857	19,453	16,552	16,852	19,840	21,440	24,047
Account Receivables	11,988	8,714	15,587	15,165	17,445	20,728	23,342
Cash and Bank Balance	30,934	37,707	18,394	25,562	24,098	32,013	42,581
Loans and Advances	5,079	4,424	7,169	11,171	12,539	10,808	12,171
Curr. Liability & Prov.	5,836	7,302	13,451	15,456	17,211	16,512	18,541
Account Payables	4,629	5,874	8,627	9,314	10,317	11,829	13,267
Other Current Liabilities	960	1,115	2,863	4,173	4,685	2,882	3,246
Provisions	248	313	1,961	1,969	2,210	1,801	2,029
Net Current Assets	54,022	62,997	44,252	53,294	56,711	68,477	83,600
Appl. of Funds	72,499	80,473	92,656	96,271	1,05,200	1,16,401	1,29,655

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Basic (INR)							
Adj. EPS	73.6	50.4	47.6	42.4	54.2	68.0	80.4
Cash EPS	80.5	59.3	68.5	65.3	79.4	92.7	107.0
BV/Share	435.6	483.2	529.7	555.4	609.6	677.6	758.0
DPS	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Payout (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Valuation (x)							
P/E	26.8	39.1	41.4	46.5	36.4	29.0	24.5
Cash P/E	24.5	33.2	28.8	30.2	24.8	21.3	18.4
P/BV	4.5	4.1	3.7	3.6	3.2	2.9	2.6
EV/Sales	6.7	7.9	5.5	5.4	4.8	4.1	3.5
EV/EBITDA	19.4	27.7	23.0	23.8	20.6	16.4	13.9
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FCF per share	16.4	8.6	36.4	31.6	-23.3	36.0	47.8
Return Ratios (%)							
RoE	18.6	11.0	9.4	7.8	9.3	10.6	11.2
RoCE	18.6	11.1	9.4	7.8	9.2	10.4	11.0
RoIC	32.5	16.6	12.9	8.7	10.1	12.5	13.6
Working Capital Ratios							
Asset Turnover (x)	2.1	1.6	1.2	1.0	1.1	1.1	1.2
Inventory (Days)	98	196	107	110	115	109	108
Debtor (Days)	99	88	100	99	101	105	105
Creditor (Days)	38	59	56	61	60	60	60
Leverage Ratio (x)							
Net Debt/Equity	-0.45	-0.47	-0.2	-0.2	-0.2	-0.3	-0.3

Consolidated - Cash Flow Statement

(INRm)

Y/E March	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
OP/(Loss) before Tax	16,186	10,546	11,325	10,627	12,981	16,002	18,935
Depreciation	1,103	1,467	3,446	3,779	4,155	4,065	4,368
Interest & Finance Charges/ (Income)	-1,352	-1,731	-1,288	-2,043	-2,367	-1,981	-2,693
Direct Taxes Paid	-4,065	-3,109	-3,062	3,538	-4,054	-4,800	-5,680
(Inc)/Dec in WC	-3,930	-4,179	-532	-61	-4,881	-3,850	-4,554
CF from Operations	7,941	2,994	9,889	15,840	5,834	9,435	10,375
Others	-33	646	79	-6,693	0	0	0
CF from Operating incl EO	7,908	3,640	9,968	9,147	5,834	9,435	10,375
(Inc)/Dec in FA	-5,217	-2,230	-3,975	-3,938	-9,665	-3,500	-2,500
Free Cash Flow	2,691	1,410	5,993	5,209	-3,831	5,935	7,875
(Pur)/Sale of Investments	-1,504	1,577	4	12	0	0	0
Others	-3,272	12,764	-13,521	20,973	2,687	2,169	2,881
CF from Investments	-9,993	12,112	-17,492	17,047	-6,978	-1,331	381
Issue of Shares	386	215	5	25	0	0	0
Inc/(Dec) in Debt	-3	-3	-7,743	-759	0	0	0
Interest Paid	-34	-63	-256	-306	-320	-188	-188
Dividend Paid	0	0	0	-3,295	0	0	0
CF from Fin. Activity	349	149	-7,994	-4,335	-320	-188	-188
Inc/Dec of Cash	-1,736	15,901	-15,518	21,860	-1,464	7,915	10,568
Opening Balance	4,925	3,188	19,089	3,571	25,430	23,966	31,882
Closing Balance	3,188	19,089	3,571	25,430	23,966	31,882	42,450
Term Deposit with Banks/Forex	27,746	18,618	14,823	132	132	132	132
Total Cash & Cash Eq	30,934	37,707	18,394	25,562	24,098	32,013	42,581

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh

Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

financial interest in the subject company

actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months

any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months

be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj

Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.